anlotinib + bempegaldesleukin

Anlotinib + bempegaldesleukin is a combination therapy consisting of anlotinib, a multi-targeted tyrosine kinase inhibitor (TKI), and bempegaldesleukin (NKTR-214), a CD122-preferential interleukin-2 (IL-2) pathway agonist. Anlotinib exerts its antineoplastic effects by inhibiting angiogenesis and tumor cell proliferation through the antagonism of VEGFR1/2/3, FGFR1/2/3/4, PDGFR alpha/beta, and c-Kit. Bempegaldesleukin is a pegylated IL-2 prodrug designed to selectively activate the IL-2 receptor beta subunit (CD122) to expand effector CD8+ T cells and natural killer (NK) cells within the tumor microenvironment while minimizing the activation of regulatory T cells (Tregs). This combination is being investigated by The First Affiliated Hospital with Nanjing Medical University, often in conjunction with conventional chemoradiotherapy (doxorubicin, ifosfamide, and radiation), for the treatment of unresectable locally advanced or metastatic soft tissue sarcoma to leverage potential synergies between anti-angiogenic targeted therapy and immune activation.

Brand names

Focus V

Other names

Anlotinib and bempegaldesleukin